CSPC
CSPC
Biomedical R&D company
CSPC, founded in June, 1992 and headquartered in Shijiazhuang, is a biopharmaceutical developer. The founder is Cai Dongchen. Listed on the HKEX on June 21, 1994, the company's major shareholders are Massive Top. Limited. Rivals that have direct and indirect competition with CSPC include 111 Group, JD health, Glaxo Smith Kline, Pfizer, etc.
- All
- News
- Analysis
- Research
Briefing Oct 08, 2021 10:27 AM
· Healthcare
Yiyi biological submitted ryzneuta to the European drug administration ™ Listing application accepted
Briefing Sep 30, 2021 02:41 PM
· Healthcare
AstraZeneca acquires Caelum Biosciences overweight rare diseases business
In depth
Healthcare
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Briefing Sep 27, 2021 11:57 AM
· Healthcare
Triarm therapeutics completed a round of financing of US $60 million
Briefing Sep 13, 2021 02:15 PM
· Healthcare
Baiji Shenzhou welcomes the milestone of "going to sea" again, and PD-1 monoclonal antibody baizean ® The new drug marketing application for esophageal squamous cell carcinoma was accepted by FDA
Research
Consumer Staples, Technology, HealthcareWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Consumer Discretionary, Consumer Staples, IndustrialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Consumer Discretionary, Consumer Staples, IndustrialsLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Briefing Sep 03, 2021 05:42 PM
· Healthcare
Nuocheng Jianhua and kangnoah deepen strategic cooperation and develop first in class macromolecular innovative drugs
Briefing Sep 03, 2021 09:45 AM
· Healthcare
Yao Ming Ju Nuo Rui Qi orenzai was approved as the second car-t product in China
Briefing Sep 03, 2021 09:38 AM
· Healthcare
Baiji Shenzhou zebutinib new indications approved by FDA
Briefing Sep 02, 2021 02:26 PM
· Healthcare
Xinda biology and JinFang medicine have reached global strategic cooperation on KRAS G12C inhibitor gfh925
Insight
Healthcare
Sinopharm COVID Vaccine Receives WHO Emergency Use Certification
The Sinopharm Group’s COVID Vaccine is the sixth vaccine to receive safety, efficacy and quality verification from the World Health Organization (WHO). It is the first vaccine from a non-Western country to receive WHO certification.
May 11, 2021 03:35 AM
Briefing Sep 01, 2021 10:57 AM
· Healthcare
YITUO pharmaceutical completed round B financing
Briefing Aug 31, 2021 05:29 PM
· Healthcare
Dashi pharmaceutical completed a round of financing of nearly 100 million yuan
Briefing Aug 31, 2021 02:03 PM
· Healthcare
Jingtai technology has reached cooperation with geode therapeutics, and important progress has been made in the research and development of tumor immune related drugs
Healthcare
Yunnan Baiyao's Revenue Rises 33%; Net Profit Falls 40% in 1Q 2021
On April 27, Yunnan Baiyao released a report for the first quarter of 2021 showing that the company's total operating revenue for the first quarter was 10.33 billion yuan, up 33.4% year-on-year; its operating profit was 880 million yuan, down 41.8% year-on-year; its net profit attributable to shareholders of the listed company was 760 million yuan.
Apr 30, 2021 02:07 AM
Briefing Aug 30, 2021 03:09 PM
· Healthcare
Yuheng biological anti-PD-1 antibody new drug approved
Briefing Jul 02, 2021 02:10 PM
· Healthcare
Li Jidian: the production capacity of next year has been fully reserved, and it can be listed before the end of the year
Briefing May 27, 2021 02:02 AM
· Healthcare
Alibaba Health Information publishes rather poor annual figures
Briefing May 13, 2021 06:43 PM
· Healthcare
HealthTech Miaoshou Doctor (Tencent Investment) ahead of IPO
See more
Related Companies
EqualOcean Analysis
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- After China's BNR and GTH Hit Nasdaq, Pan-Cancer Detector GRAIL Eyes IPO
- Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
- More Room for the Medical Device Market to Grow in China
- Modern Chinese Medicine Maker Tasly Pharmaceutical: An Old Stock in a New Package?
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.